HU

Hospital Universitario Puerta de Hierro Majadahonda at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Hospital Universitario Puerta de Hierro Majadahonda takes part in 8 sessions at ESMO 2026 in Madrid. Its program centres on non-small cell lung cancer, from immunotherapy around surgery to local therapy in advanced disease, and on ovarian, endometrial and cervical cancers, including antibody-drug conjugates. Other sessions cover financial toxicity and equitable access to treatment.

OrganizationESMO 2026 Attendance
HU
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, Spain
Cancer centre & hospital
Public university hospital of the Madrid regional health service in Majadahonda, Spain, and a teaching hospital of the Autonomous University of Madrid.
Satellite
Fri Oct 23
09:45–11:15
Satellite
Fri Oct 23
09:45–11:15
Bristol Myers Squibb - Optimizing the NSCLC Treatment Landscape: Impact for Today and Insights for Tomorrow
with European Institute of Oncology (IEO), Vall d'Hebron University Hospital
Lung & thoracic cancers
Satellite
Fri Oct 23
09:45–10:00
New Currents, New Directions: The Evolving Ovarian Cancer Treatment Paradigm
AbbVie - Riding the Wave of Innovation Towards Personalized Medicine in Ovarian Cancer
Gynaecological cancers
Satellite
Fri Oct 23
09:45–09:50
Welcome and Introductions
Bristol Myers Squibb - Optimizing the NSCLC Treatment Landscape: Impact for Today and Insights for Tomorrow
Lung & thoracic cancers
Satellite
Fri Oct 23
09:50–10:10
Exploring the Many Faces of NSCLC Management
Bristol Myers Squibb - Optimizing the NSCLC Treatment Landscape: Impact for Today and Insights for Tomorrow
Lung & thoracic cancers
Satellite
Fri Oct 23
10:50–11:10
Keeping the Patient in the Center
Bristol Myers Squibb - Optimizing the NSCLC Treatment Landscape: Impact for Today and Insights for Tomorrow · with International Cancer Advocacy Network (ICAN), European Institute of Oncology (IEO), Vall d'Hebron University Hospital
Lung & thoracic cancers
Chair
Fri Oct 23
16:15–17:30
Optimising use of local therapy in advanced lung cancer: Why, when, and how
with Guangdong Provincial People's Hospital
Lung & thoracic cancers
Talk
Fri Oct 23
16:20–16:40
Medical oncology perspective
Optimising use of local therapy in advanced lung cancer: Why, when, and how
Lung & thoracic cancers
Satellite
Sat Oct 24
13:00–14:30
Satellite
Sat Oct 24
13:00–13:15
The Evolving Landscape in Endometrial and Ovarian Cancers
GSK - From Discovery to Impact: ADCs in Endometrial and Ovarian Cancer Care
Gynaecological cancers
Satellite
Sat Oct 24
13:15–13:20
Audience polling
GSK - From Discovery to Impact: ADCs in Endometrial and Ovarian Cancer Care · with Centre Léon Bérard, University of California San Diego
Gynaecological cancers
Talk
Sun Oct 25
10:30–10:45
Financial toxicity and equity (access to treatment)
Equitable health care of underserved population
Nursing & supportive care
Satellite
Sun Oct 25
13:00–13:05
Welcome and Introductions
BeOne Medicines - Data, Debate, and New Directions in the NSCLC Continuum:​From Early-Stage Immunotherapy to New Modalities in Advanced Disease · with University of Turin
Lung & thoracic cancers
Satellite
Sun Oct 25
13:05–13:20
What We Know and Don’t Know About Immunotherapy in Resectable NSCLC
BeOne Medicines - Data, Debate, and New Directions in the NSCLC Continuum:​From Early-Stage Immunotherapy to New Modalities in Advanced Disease
Lung & thoracic cancers
Satellite
Sun Oct 25
13:20–14:05
Neoadjuvant vs Perioperative Immunotherapy: An Expert Clinical Debate
BeOne Medicines - Data, Debate, and New Directions in the NSCLC Continuum:​From Early-Stage Immunotherapy to New Modalities in Advanced Disease · with University Hospital Cologne, Trinity St James's Cancer Institute, University of Turin +1 more
Lung & thoracic cancers
Satellite
Sun Oct 25
14:25–14:30
Close
BeOne Medicines - Data, Debate, and New Directions in the NSCLC Continuum:​From Early-Stage Immunotherapy to New Modalities in Advanced Disease · with University of Turin
Lung & thoracic cancers
Chair
Sun Oct 25
14:45–16:15
Cervical cancer: From prevention to optimal therapy
with Medical University of Innsbruck
Gynaecological cancers
Talk
Sun Oct 25
15:25–15:45
Optimal systemic therapy for persistent, recurrent or metastatic disease
Cervical cancer: From prevention to optimal therapy
Gynaecological cancers

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Hospital Universitario Puerta de Hierro Majadahonda

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction